To compare the efficacy of ALVR105 to placebo in the proportion of patients with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection and/or end-organ disease as determined by an independent, blinded Clinical Adjudication Committee (CAC) through Week 14
Adult
Prevention
University of Colorado Hospital
Jonathan Gutman, MD
Protocol Number: 20-2670
More information available at ClinicalTrials.gov: NCT04693637
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers